Healing enhancement of diabetic wounds by locally infiltrated epidermal growth factor is associated with systemic oxidative stress reduction
- 22 March 2016
- journal article
- Published by Wiley in International Wound Journal
- Vol. 14 (1) , 214-225
Abstract
The diabetic foot ulcer (DFU) is the leading cause of lower extremity amputation worldwide and is directly associated with comorbidity, disability and mortality. Oxidative stress mechanisms have been implicated in the pathogenesis of these wounds. Intra‐lesional infiltration of epidermal growth factor has emerged as a potential therapeutic alternative to allow for physiological benefit while avoiding the proteolytic environment at the centre of the wound. The aim of this study was to characterise the response of patients with DFUs to epidermal growth factor treatment in terms of redox status markers. Experimental groups included patients with DFUs before and 3–4 weeks after starting treatment with epidermal growth factor; compensated and non‐compensated diabetic patients without ulcers; and age‐matched non‐diabetic subjects. Evaluations comprised serum levels of oxidative stress and antioxidant reserve markers. Patients with DFUs exhibited the most disheveled biochemical profile, with elevated oxidative stress and low antioxidant reserves, with respect to non‐ulcerated diabetic patients and to non‐diabetic subjects. Epidermal growth factor intra‐lesional administration was associated with a significant recovery of oxidative stress and antioxidant reserve markers. Altogether, our results indicate that epidermal growth factor intra‐ulcer therapy contributes to restore systemic redox balance in patients with DFUs.Keywords
Funding Information
- BioCubaFarma Central Research Office
This publication has 57 references indexed in Scilit:
- Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcersBMC Pharmacology and Toxicology, 2013
- Granulation Response and Partial Wound Closure Predict Healing in Clinical Trials on Advanced Diabetes Foot Ulcers Treated With Recombinant Human Epidermal Growth FactorDiabetes Care, 2013
- Glucose Toxic Effects on Granulation Tissue Productive Cells: The Diabetics’ Impaired HealingBioMed Research International, 2012
- Pentosidine as a biomarker for microvascular complications in type 2 diabetic patientsDiabetes & Vascular Disease Research, 2012
- Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetesExperimental Gerontology, 2011
- Oxidative stress, insulin signaling, and diabetesFree Radical Biology and Medicine, 2011
- Oxidative Stress and Diabetic ComplicationsCirculation Research, 2010
- The clinical relevance of assessing advanced glycation endproducts accumulation in diabetesCardiovascular Diabetology, 2008
- Glycated haemoglobin (HbA 1c ) monitoringBMJ, 2006
- The Dysvascular Foot: A System for Diagnosis and TreatmentFoot & Ankle, 1981